Cause-specific mortality among HIV-infected individuals, by CD4R cell count at HAART initiation, compared with HIV-uninfected individuals

AIDS

Volumn 28, Issue 2, 2014, Pages 257-265

  Wada, Nikolas ^a   Jacobson, Lisa P ^a   Cohen, Mardge ^b   French, Audrey ^b   Phair, John ^c   Muñoz, Alvaro ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b RUSH UNIVERSITY   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiretroviral therapy; Bias; CD4+cell count; Cohort studies,competing risks; Mortality; Statistical

Indexed keywords

CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ARTICLE; BISEXUAL MALE; CELL COUNT; COHORT ANALYSIS; COMPARATIVE STUDY; FEMALE; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; VIRUS HEPATITIS;

ADULT; AGED; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 84892173855     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000078     Document Type: Article

References (30)

1. Porter K, Babiker A, Bhaskaran K,Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003; 362:1267-1274.
2. Wada N, Jacobson L, Cohen M, French AL, Phair JP, Muñoz A. Cause-specific life expectancies after age 35 for HIVinfected and HIV-negative individuals followed simultaneously in long-term cohort studies: 1984-2008. Am J Epidemiol 2013; 177:116-125.
3. Egger M, May M, Chene G, Phillips AN, Ledergerber B, Dabis F, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119-129.
4. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, Moorman AC, Wood KC, Greenberg AE, et al. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4R cell strata. Ann Intern Med 2003; 138:620-626.
5. Sterling TR, Chaisson RE, Keruly J, Moore RD. Improved outcomes with earlier initiation of highly active antiretroviral therapy among human immunodeficiency virus-infected patients who achieve durable virologic suppression: longer follow-up of an observational cohort study. J Infect Dis 2003; 188:1659-1665.
6. Wang C, Vlahov D, Galai N, Bareta J, Strathdee SA, Nelson KE, et al. Mortality in HIV-seropositive versus-seronegative persons in the era of highly active antiretroviral therapy: implications for when to initiate therapy. J Infect Dis 2004; 190:1046-1054.
7. Lewden C, Chene G, Morlat P, Raffi F, Dupon M, Dellamonica P, et al. HIV-infected adults with a CD4 cell count greater than 500 cells/mm3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007; 46:72-77.
8. Muga R, Langohr K, Tor J, Sanvisens A, Serra I, Rey-Joly C, et al. Survival of HIV-infected injection drug users (IDUs) in the highly active antiretroviral therapy era, relative to sex-and age-specific survival of HIV-uninfected IDUs. Clin Infect Dis 2007; 45:370-376.
9. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-1826.
10. Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, Harris R, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373:1352-1363.
11. Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123-137.
12. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Washington, DC: Department of Health and Human Services; 2013.
13. Miller V, Horberg MA. Getting to normal: are we there yet? AIDS 2013; 27:1027-1028.
14. Monforte A, Abrams D, Pradier C, Weber R, Reiss P, Bonnet F, et al. HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. AIDS 2008; 22:2143-2153.
15. Shapiro MF, Morton SC, McCaffrey DF, Senterfitt JW, Fleishman JA, Perlman JF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA 1999; 281:2305-2315.
16. Moore RD, Keruly JC, Chaisson RE. Differences in HIV disease progression by injecting drug use in HIV-infected persons in care. J Acquir Immune Defic Syndr 2004; 35:46-51.
17. French AL, Gawel SH, Hershow R, Benning L, Hessol NA, Levine AM, et al. Trends in mortality and causes of death among women with HIV in the United States: a 10-year study. J Acquir Immune Defic Syndr 2009; 51:399-406.
18. Rubin M. Examination of inequalities in HIV/AIDS mortality in the United States from a fundamental cause perspective. Am J Public Health 2010; 100:1053-1059.
19. Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psychol Measur 1977; 1:385-401.
20. Checkley W, Brower RG, Muñoz A. Inference for mutually exclusive competing events through a mixture of generalized gamma distributions. Epidemiology 2010; 21:557-565.
21. Cox C. Delta method. In: Armitage P, Colton T,editors. Encyclopedia of biostatistics New York: John Wiley; 1998. pp. 1125-1127.
22. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multistate models. Stat Med 2007; 26:2389-2430.
23. Lu K, Jiang L, Tsiatis A. Multiple imputation approaches for the analysis of dichotomized responses in longitudinal studies with missing data. Biometrics 2010; 66:1201-1208.
24. Bakoyannis G, Siannis F, Touloumi G. Modelling competing risks data with missing cause of failure. Stat Med 2010; 29:3172-3185.
25. Sabin CA. Early antiretroviral therapy: the role of cohorts. Curr Opin HIV AIDS 2009; 4:200-205.
26. Ahdieh L, Yamashita TE, Phair JP, Detels R, Wolinsky SM, Margolick J, et al. When to initiate highly active antiretroviral therapy: a cohort approach. Am J Epidemiol 2003; 157:738-746.
27. Cole SR, Li R, Anastos K, Detels R, Young M, Chmiel JS, et al. Accounting for leadtime in cohort studies: evaluating when to initiate HIV therapies. Stat Med 2004; 23:3351-3363.
28. Rubin DB, Schenker N. Multiple imputation in healthcare databases: an overview and some applications. Stat Med 1991; 10:585-598.
29. Ahdieh L, Gange SJ, Greenblatt R, Minkoff H, Anastos K, Young M, et al. Selection by indication of potent antiretroviral therapy use in a large cohort of women infected with human immunodeficiency virus. Am J Epidemiol 2000; 152:923-933.
30. Institute of Medicine. HIV screening and access to care: healthcare system capacity for increased HIV testing and provision of care. Washington, DC: The National Academies Press; 2011.